• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$29.56 $0.20 (0.68%)

REAL-TIME: Last trade at

Hi-Tech Pharmacal Co.

NASDAQ:HITK

Jump to this page for:

Related Resources

Hi-Tech Pharmacal to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

5/14/2012 by PharmiWeb.com - UK

Hi-Tech Pharmacal to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

5/14/2012 by Business Wire

Hi-Tech Pharmacal initiated with a Buy at Standpoint Research

5/7/2012 by Theflyonthewall.com

Standpoint Research Starts Hi Tech Pharmacal (HITK) at Buy; Large Pipeline

5/7/2012 by StreetInsider.com

Hi-Tech Pharmacal Licenses Rights to Lidocaine 5% Ointment

4/26/2012 by PharmiWeb.com - UK

Hi-Tech Pharmacal licenses rights to Lidocaine 5% ointment

4/26/2012 by Theflyonthewall.com

Hi-Tech Pharmacal Licenses Rights to Lidocaine 5% Ointment

4/26/2012 by Business Wire

James Investment Research targets stocks in favored industries, Barron's says

4/1/2012 by Theflyonthewall.com

UPS Likes Europe? (LDK, UPS, ABVT, AAPL, HITK, YONG)

3/19/2012 by tickerspy.com

Needham & Company Maintains a 'Hold' on Hi Tech Pharmacal (HITK); Upside Momentum Stalls Out In 3Q

3/9/2012 by StreetInsider.com

Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Updating Model

3/9/2012 by StreetInsider.com

Hi-Tech Pharmacal Acquires A Line Of Branded Homeopathic Nasal Spray Products

3/9/2012 by Pharmaceutical Online

Hi-Tech Pharmacal buys homeopathic product line from Dynova Labs

3/8/2012 by Drug Store News

Hi-Tech Pharmacal reports Q3 EPS 79c, consensus 83c

3/8/2012 by Theflyonthewall.com

Hi-Tech Pharmacal acquires branded homeopathic nasal spray products

3/8/2012 by Theflyonthewall.com

Hi-Tech Pharmacal Reports Sales of $55.6 Million and EPS of $0.79 for the Third Quarter Ended January 31, 2012

3/8/2012 by Business Wire

Hi-Tech Pharmacal Acquires a Line of Branded Homeopathic Nasal Spray Products

3/8/2012 by Business Wire

Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Lowering FQ3 on Softer Anticipated Cough and Cold Season

3/6/2012 by StreetInsider.com

Hi-Tech Pharmacal to Release Third Quarter Earnings and Hold Conference Call on March 8, 2012

3/2/2012 by Business Wire

FDA approves Hi-Tech Pharmacal epilepsy drug

2/29/2012 by Drug Store News

Hi-Tech Pharmacal's Levetiracetam Oral Solution granted final FDA approval

2/29/2012 by Theflyonthewall.com

Hi-Tech Pharmacal to Present at the 2012 RBC Capital Markets’ Global Healthcare Conference

2/28/2012 by StockWatch

Hi-Tech Pharmacal to Present at the 2012 RBC Capital Markets’ Global Healthcare Conference

2/28/2012 by Business Wire

Hi-Tech Pharmacal receives final approval for Lorazepam oral concentrate

1/31/2012 by Theflyonthewall.com

Hi-Tech Pharmacal’s ECR Pharmaceuticals Subsidiary Launches Hylase® Wound Gel

1/18/2012 by PharmiWeb.com - UK

Hi-Tech Pharmacal unit launches Hylase wound gel

1/18/2012 by Theflyonthewall.com

Hi-Tech Pharmacal’s ECR Pharmaceuticals Subsidiary Launches Hylase® Wound Gel

1/18/2012 by Business Wire

Canaccord Genuity Reiterates a 'Buy' on Hi Tech Pharmacal (HITK) on Sell-off Post Checks, Management Meeting

1/11/2012 by StreetInsider.com

Even Beaten-Down Financial Stocks Popular Today (LULU, TIF, CRUS, WBMD, AA, BAC, IPGP, HITK)

1/10/2012 by tickerspy.com

Hi-Tech Pharmacal falls 14.7%

1/10/2012 by Theflyonthewall.com

Audiovox, Eastman Kodak, Emulex, Hi-Tech Pharmacal: U.S. Equity Movers

1/10/2012 by Bloomberg.com

Hi-Tech Pharmacal (HITK) Slammed On Generic Flonase Competition

1/10/2012 by StreetInsider.com

Wockhardt gets FDA approval for generic Flonase, Pharmabiz reports

1/10/2012 by Theflyonthewall.com

Canaccord Genuity Starts Hi Tech Pharmacal (HITK) at Buy; Well Positioned High-Barrier Platform with Strategic Value

1/5/2012 by StreetInsider.com

Hi-Tech Pharmacal initiated with a Buy at Canaccord

1/5/2012 by Theflyonthewall.com

Earnings Surprises: Short-Sellers Think These Stocks Have More Upside

12/21/2011 by The Motley Fool

Hi-Tech Pharmacal (HITK) - Zacks #1 Rank Top Performers

12/12/2011 by Zacks Investment Research

HiTech Pharmacal Co. Inc. Reports Operating Results (10-Q)

12/8/2011 by GuruFocus

Can These Stocks Bounce Back?

12/7/2011 by The Motley Fool

In Interconnected World, China Slowdown a Worry Too (DG, IMKTA, YUM, SFSF, SAP, HITK)

12/5/2011 by tickerspy.com
See More Articles...